Full text
Earnings transcript
Read the complete earnings call transcript.
CNMD
CONMED Corporation
$51.89
-1.77
(-3.3%)
| Exchange: | NYSE |
| Market Cap: | 1.546B |
| Shares Outstanding: | 31.036M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – DevicesView industry performance | |||||
| CEO: | Patrick J. Beyer | |||||
| Full Time Employees: | 3900 | |||||
| Address: |
| |||||
| Website: | https://www.conmed.com |
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Click to read more…
Revenue Segmentation
Revenue by type
Revenue by region
CNMD full analysis
Welcome to MARKETSNAP’s SWOT analysis for CONMED Corporation, a player in the medical technology space that might not be on everyone’s radar but definitely deserves a closer look. If you’re a long-term investor hunting for opportunities in the healthcare sector, stick around as we break down what makes CONMED tick, where it’s shining, and where it might be stumbling. Let’s dive into the details with a conversational deep dive into their business, recent performance, and a full SWOT to help…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,244,744 | 1,307,015 | 1,374,495 |
| Gross Profit | 676,245 | 733,032 | 725,375 |
| EBITDA | 172,003 | 251,631 | 176,485 |
| Operating Income | 120,603 | 200,326 | 141,131 |
| Net Income | 64,459 | 132,423 | 47,055 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 2,300,021 | 2,306,247 | 2,325,749 |
| Total Liabilities | 1,465,799 | 1,343,566 | 1,292,652 |
| Total Stockholders Equity | 834,222 | 962,681 | 1,033,097 |
| Total Debt | 991,254 | 905,781 | 834,942 |
| Cash and Cash Equivalents | 24,296 | 24,459 | 40,817 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 125,348 | 166,968 | 170,689 |
| Capital Expenditure | -19,032 | -13,084 | -19,806 |
| Free Cash Flow | 106,316 | 153,884 | 150,883 |
| Net Income | 64,459 | 132,423 | 47,055 |
| Net Change in Cash | -4,646 | 163 | 16,358 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,628,275.319 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,640,401.691 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,635,152.500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 327,666.534 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 330,107.105 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 329,050.794 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 207,808.068 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 209,822.474 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 208,950.613 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 651,032.598 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 655,881.080 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 653,782.298 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 6.710 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 6.740 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 6.670 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Performance: CNMD reported total sales of $342.3 million in Q2 2025, slightly exceeding the high end of guidance, reflecting strong demand and effective market positioning within the medical technology sector.
- Operational Efficiency Gains: The company is actively optimizing operations, with initiatives expected to yield significant annual savings and improve execution, as highlighted in the Q2 2025 earnings call.
- Positive Free Cash Flow: Recent cash flow statements indicate consistent free cash flow generation, supported by net cash provided by operating activities, providing financial flexibility for reinvestment or debt management.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates CNMD intrinsic value between $93.06 – $128.35 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CNMD valuation
Is CONMED Corporation (CNMD) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for CONMED Corporation (CNMD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CNMD a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CNMD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CNMD’s P/E ratio?
You can see CNMD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CNMD?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CNMD a good long-term investment?
Whether CNMD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CNMD
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-3.3
Trading Metrics:
| Open: | 54.4 | Previous Close: | 53.66 | |
| Day Low: | 51.7 | Day High: | 54.56 | |
| Year Low: | 31.44 | Year High: | 54.56 | |
| Price Avg 50: | 46.95 | Price Avg 200: | 41.52 | |
| Volume: | 162108 | Average Volume: | 488529 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
